Last reviewed · How we verify
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
The purpose of this study is to see if the combination of bendamustine, lenalidomide and dexamethasone will help people with multiple myeloma that has returned after standard treatment or has been resistant to other treatments.
Details
| Lead sponsor | Robert Redner, MD |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 29 |
| Start date | 2008-02 |
| Completion | 2015-03 |
Conditions
- Myeloma
Interventions
- Bendamustine
- Lenalidomide
- Dexamethasone
- Aspirin
- Prophylaxis
- Antibiotic
- Biweekly Follow Up
- Cyclical Follow Up
- Restaging
- Post-Treatment Follow Up
Primary outcomes
- To establish the dose of each drug recommended for a future Phase II protocol with the combination — 1 year
Countries
United States